Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Approval strengthens the company’s growing international anti-infective portfolio
Supported by Plan International, the partnership will help treat over 1,000 children annually
Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
The initiative by DKMS Foundation India is for below 12 years children suffering from transfusion-dependent thalassemia
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Subscribe To Our Newsletter & Stay Updated